$SMMT
Summit Therapeutics Inc. Stock $smmt

$smmt Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000159929824000085 Filed on May 01, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$30.80M	$30.87M
YoY Change	225.87%	212.38%
% of Gross Profit
Depreciation & Amortization	$20.00K	$27.00K
YoY Change	-56.52%	-70.0%
% of Gross Profit
Operating Expenses	$59.78M	$42.60M
YoY Change	279.12%	-92.08%
Operating Profit	-$59.62M	-$42.39M
YoY Change	277.47%	-92.11%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$768.0K	-$1.084M
YoY Change	-171.31%	-79.24%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$60.39M	-$43.47M
YoY Change	310.31%	-91.98%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.09	-$0.06
Diluted Earnings Per Share	-$0.09	-$0.06
COMMON SHARES
Basic Shares Outstanding	702.0M shares	701.7M shares
Diluted Shares Outstanding	707.9M shares	701.8M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$325.5M	$156.7M
YoY Change	51.37%	-35.24%
Cash & Equivalents	$28.43M	$61.29M
Short-Term Investments	$297.0M	$95.39M
Other Short-Term Assets	$2.372M	$5.640M
YoY Change	32.74%	1278.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$328.8M	$163.3M
YoY Change	44.52%	-34.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$223.0K	$181.0K
YoY Change	-0.89%	-56.07%
Goodwill	$1.880M	$1.875M
YoY Change	-0.16%	1.96%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.879M	$1.875M
YoY Change	639.76%	1101.92%
Total Long-Term Assets	$13.06M	$13.52M
YoY Change	32.33%	96.74%
TOTAL ASSETS
Total Short-Term Assets	$328.8M	$163.3M
Total Long-Term Assets	$13.06M	$13.52M
Total Assets	$341.9M	$176.8M
YoY Change	44.02%	-30.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.340M	$6.371M
YoY Change	238.4%	797.32%
Accrued Expenses	$12.46M	$6.547M
YoY Change	222.05%	-46.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$100.0M
YoY Change
Total Short-Term Liabilities	$140.2M	$23.44M
YoY Change	1074.82%	34.37%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$100.0M
YoY Change	-100.0%	0.0%
Other Long-Term Liabilities	$1.596M	$3.310M
YoY Change	5.63%	123.5%
Total Long-Term Liabilities	$1.596M	$3.310M
YoY Change	5.63%	123.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$140.2M	$23.44M
Total Long-Term Liabilities	$1.596M	$3.310M
Total Liabilities	$146.8M	$132.6M
YoY Change	24.63%	9.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.097B	-$1.037B
YoY Change	17.29%	12.6%
Common Stock	$7.243M	$7.020M
YoY Change	3.83%	0.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$195.1M	$44.21M
YoY Change
Total Liabilities & Shareholders Equity	$341.9M	$176.8M
YoY Change	44.02%	-30.65%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$60.39M	-$43.47M
YoY Change	310.31%	-91.98%
Depreciation, Depletion And Amortization	$20.00K	$27.00K
YoY Change	-56.52%	-70.0%
Cash From Operating Activities	-$33.00M	-$30.13M
YoY Change	12.74%	129.49%
INVESTING ACTIVITIES
Capital Expenditures	$63.00K	$4.000K
YoY Change	215.0%	-92.45%
Acquisitions
YoY Change
Other Investing Activities	-$200.0M	$19.88M
YoY Change	-88212.78%	-103.08%
Cash From Investing Activities	-$200.1M	$19.87M
YoY Change	-96756.52%	-103.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	200.2M	$485.0K
YoY Change	-250365.0%	-99.39%
NET CHANGE
Cash From Operating Activities	-33.00M	-$30.13M
Cash From Investing Activities	-200.1M	$19.87M
Cash From Financing Activities	200.2M	$485.0K
Net Change In Cash	-32.87M	-$9.814M
YoY Change	12.77%	-98.3%
FREE CASH FLOW
Cash From Operating Activities	-$33.00M	-$30.13M
Capital Expenditures	$63.00K	$4.000K
Free Cash Flow	-$33.07M	-$30.14M
YoY Change	12.88%	128.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	133482000	usd
CY2023Q4	us-gaap	Notes Payable Noncurrent Related Party Type Extensible Enumeration NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2024Q1	us-gaap	Notes Payable Noncurrent Related Party Type Extensible Enumeration NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	23438000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20405000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5823000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3290000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3310000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1562000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	419000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	701974596	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	701974596	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	701660053	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	701660053	shares
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30873000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9883000	usd
CY2024Q1	smmt	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	0	usd
CY2023Q1	smmt	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	520915000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11729000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6940000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	42602000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	537738000	usd
CY2024Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	213000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	584000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-42389000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-537154000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1084000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5222000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-43473000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-542376000	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.43
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.43
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	701785250	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	701785250	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	378163980	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	378163980	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-43473000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-542376000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-12000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-51000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	11000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	968000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43474000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-541878000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	77692000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	485000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9507000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-43473000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	44210000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126654000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	619000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	499381000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	651000	usd
CY2023Q1	smmt	Stock Issued During Period Value In Lieu Of Cash For Collaborative Arrangement StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement	45900000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2775000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	497000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-542376000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-43473000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-542376000	usd
CY2024Q1	smmt	Interest Expense Income Noncash InterestExpenseIncomeNoncash	0	usd
CY2023Q1	smmt	Interest Expense Income Noncash InterestExpenseIncomeNoncash	6063000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	402000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-9000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	470000	usd
CY2024Q1	smmt	Cumulative Currency Translation Gains Losses Realized Upon Sale Or Liquidation Reclassified From Other Comprehensive Income CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome	0	usd
CY2023Q1	smmt	Cumulative Currency Translation Gains Losses Realized Upon Sale Or Liquidation Reclassified From Other Comprehensive Income CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome	419000	usd
CY2024Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	474000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	27000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	90000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9507000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2775000	usd
CY2024Q1	smmt	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	0	usd
CY2023Q1	smmt	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	520915000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-350000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2792000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-331000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2531000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-508000	usd
CY2024Q1	smmt	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	-632000	usd
CY2023Q1	smmt	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	-850000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3704000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	308000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2154000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	730000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1763000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
CY2024Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	606000	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3238000	usd
CY2024Q1	smmt	Increase Decrease In Operating Lease Right Of Use Asset And Operating Lease Liability Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndOperatingLeaseLiabilityNet	92000	usd
CY2023Q1	smmt	Increase Decrease In Operating Lease Right Of Use Asset And Operating Lease Liability Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndOperatingLeaseLiabilityNet	22000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30134000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13131000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	53000	usd
CY2024Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	92982000	usd
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	169995000	usd
CY2024Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	112857000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	usd
CY2024Q1	smmt	Payments For Collaborative Arrangement PaymentsForCollaborativeArrangement	0	usd
CY2023Q1	smmt	Payments For Collaborative Arrangement PaymentsForCollaborativeArrangement	475015000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19871000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-645063000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	104686000	usd
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	539000	usd
CY2024Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	24686000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	485000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	651000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	485000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80112000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-36000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	444000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9814000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-577638000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71425000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	648607000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61611000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70969000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	1501000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1306000	usd
CY2024Q1	smmt	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	usd
CY2023Q1	smmt	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	80000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4216000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business and Operations<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nature of Business and Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Summit Therapeutics Inc. (“we”, “Summit” or the “Company”) is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. On December 5, 2022, the Company entered into a Collaboration and License Agreement (the “License Agreement”) with Akeso, Inc. and its affiliates (“Akeso”) pursuant to which the Company has in-licensed ivonescimab as further described in Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Through the License Agreement, the Company obtained the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan (the “Licensed Territory”). The License Agreement and transaction closed in January 2023 following customary waiting periods. The Company’s operations will be focused on the development of ivonescimab and other future activities, as the Company determines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has begun its development for ivonescimab in non-small cell lung cancer (“NSCLC”), specifically launching Phase III clinical trials in the following indications:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a) ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (“EGFR”)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (“TKI”) (“HARMONi”); and</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b) ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (“HARMONi-3”)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of the date of these financial statements, both studies are enrolling patients.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The entry into the License Agreement with Akeso represents a significant change in the Company’s strategy and its future operations will be focused on the development of ivonescimab and other future activities as the Company determines.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s portfolio also includes ridinilazole, a product candidate for treating patients suffering from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Clostridioides difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">infection, also known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">C. difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">infection, or CDI, and SMT-738, the first of a novel class of precision antibiotics for combating multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae (“CRE”) infections. All prior development activities related to ridinilazole and SMT-738 have been terminated; the Company will continue to pursue partnerships for both assets.</span></div>
CY2024Q1	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation and Use of Estimates<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and disclosures required by U.S. GAAP for complete consolidated financial statements are not included herein. All intercompany accounts and transactions have been eliminated in consolidation. The interim financial data as of March 31, 2024 and for the three months ended March 31, 2024 are unaudited; however, in the opinion of management, the interim data includes all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The condensed consolidated balance sheet presented as of December 31, 2023 has been derived from the consolidated audited financial statement as of that date. The results of the period are not necessarily indicative of full year results or any other interim period. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto of the Company which are included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission on February 20, 2024. The financial results of the Company's activities are reported in United States Dollars</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting policies are consistent with the Notes to the Consolidated Financial Statement in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission, except as updated below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of non-interest-bearing deposits denominated in the U.S. dollar and British pound, and the Company invested cash in money market funds and U.S. treasury securities. All highly liquid investments with a maturity date of 90 days or less at the date of purchase are considered to be cash equivalents. The appropriate classification of investments in securities as to whether it is classified as a cash equivalent is determined by the Company at the time of purchase.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of investments with original maturities greater than ninety days from the date of acquisition. The Company classifies investments with maturities of greater than 90 days as short-term, based on the liquid nature of the securities and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of investments as available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices or other observable inputs. Unrealized gains and losses are recorded as a component of other comprehensive income (loss). Realized gains and losses are determined on a specific identification basis and are included in other (expense) income. Amortization and accretion of discounts and premiums is also recorded in other (expense) income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the fair value is below the amortized cost of the asset, an estimate of expected credit losses is made, this estimate is limited to the amount by which fair value is less than amortized cost. The credit-related impairment amount is recognized in the condensed consolidated statements of operations and comprehensive loss and the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income (loss) in shareholders’ equity. Credit losses are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis the allowance for credit loss is written off and the excess of the amortized cost basis of the asset over its fair value is recorded in the condensed consolidated statements of operations and comprehensive loss..</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of these unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div>
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of these unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div>
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-43473000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30134000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1036731000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61294000	usd
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	95386000	usd
CY2024Q1	smmt	Research And Development Tax Credit Receivable ResearchAndDevelopmentTaxCreditReceivable	1157000	usd
CY2024Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	100000000	usd
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	152489000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	175174000	usd
CY2024Q1	us-gaap	Cash Cash	4191000	usd
CY2024Q1	us-gaap	Number Of Countries In Which Entity Operates NumberOfCountriesInWhichEntityOperates	2	country
CY2024Q1	us-gaap	Noncurrent Assets NoncurrentAssets	9554000	usd
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	6062000	usd
CY2024Q1	smmt	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	213000	usd
CY2023Q1	smmt	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	542000	usd
CY2024Q1	smmt	Grant Funding Arrangement Income Earned GrantFundingArrangementIncomeEarned	0	usd
CY2023Q1	smmt	Grant Funding Arrangement Income Earned GrantFundingArrangementIncomeEarned	34000	usd
CY2024Q1	smmt	Other Operating Income Other OtherOperatingIncomeOther	0	usd
CY2023Q1	smmt	Other Operating Income Other OtherOperatingIncomeOther	8000	usd
CY2024Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	213000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	584000	usd
CY2024Q1	smmt	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	945000	usd
CY2024Q1	smmt	Research And Development Tax Credit Receivable Noncurrent ResearchAndDevelopmentTaxCreditReceivableNoncurrent	212000	usd
CY2023Q4	smmt	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	848000	usd
CY2023Q4	smmt	Research And Development Tax Credit Receivable Noncurrent ResearchAndDevelopmentTaxCreditReceivableNoncurrent	959000	usd
CY2021Q2	smmt	Grant Funding Arrangement Maximum Funding Value GrantFundingArrangementMaximumFundingValue	4100000	usd
CY2021Q2	smmt	Grant Funding Arrangement Milestone Funding Increase GrantFundingArrangementMilestoneFundingIncrease	3700000	usd
	smmt	Grant Funding Arrangement Income Earned GrantFundingArrangementIncomeEarned	2920000	usd
CY2023Q1	smmt	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	520915000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	208000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	508000	usd
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	3121000	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	8327000	usd
CY2024Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1829000	usd
CY2023Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1761000	usd
CY2024Q1	smmt	Cumulative Currency Translation Gains Losses Realized Upon Sale Or Liquidation Reclassified From Other Comprehensive Income CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome	0	usd
CY2023Q1	smmt	Cumulative Currency Translation Gains Losses Realized Upon Sale Or Liquidation Reclassified From Other Comprehensive Income CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome	419000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	417000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1084000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5222000	usd
CY2023Q1	smmt	Cumulative Currency Translation Gains Losses Realized Upon Sale Or Liquidation Reclassified From Other Comprehensive Income CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome	419000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-43473000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-542376000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	701785250	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	378163980	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	701785250	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	378163980	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.43
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.43
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	59995475	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26207731	shares
CY2024Q1	smmt	Other Commitment Period For Which The Majority Of Commitments Are To Be Paid OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid	P1Y
CY2023Q4	us-gaap	Cash Cash	11068000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	95375000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	95386000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	114781000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	36000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	114817000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	1875000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1893000	usd
CY2024Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	usd
CY2024Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	317000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9373000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5859000	usd
CY2024Q1	smmt	Research And Development Prepaid Expenses Current ResearchAndDevelopmentPrepaidExpensesCurrent	4351000	usd
CY2023Q4	smmt	Research And Development Prepaid Expenses Current ResearchAndDevelopmentPrepaidExpensesCurrent	1466000	usd
CY2024Q1	smmt	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	6074000	usd
CY2023Q4	smmt	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	7289000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9507000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2775000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9507000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2775000	usd
CY2024Q1	smmt	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	5015642	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5015642	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5015642	shares
CY2023Q4	smmt	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	5015642	shares
CY2024Q1	smmt	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	1.57
CY2023Q4	smmt	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	1.57
CY2023Q4	smmt	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	1.57
CY2024Q1	smmt	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	1.57

Files In Submission

Name	View Source	Status
0001599298-24-000085-index-headers.html	Edgar Link	pending
0001599298-24-000085-index.html	Edgar Link	pending
0001599298-24-000085.txt	Edgar Link	pending
0001599298-24-000085-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_13a.jpg	Edgar Link	pending
image_22a.jpg	Edgar Link	pending
image_24a.jpg	Edgar Link	pending
image_26a.jpg	Edgar Link	pending
image_27a.jpg	Edgar Link	pending
image_28a.jpg	Edgar Link	pending
image_29a.jpg	Edgar Link	pending
image_30a.jpg	Edgar Link	pending
image_31a.jpg	Edgar Link	pending
image_33a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
smmt-20240331.htm	Edgar Link	pending
smmt-20240331.xsd	Edgar Link	pending
smmt-20240331_g1.jpg	Edgar Link	pending
smmt-20240331_g2.jpg	Edgar Link	pending
sum-ex101xamendedemploymen.htm	Edgar Link	pending
sum-ex102leasexsummitthera.htm	Edgar Link	pending
sum-ex311_20240331xduggan.htm	Edgar Link	pending
sum-ex312_20240331xzanganeh.htm	Edgar Link	pending
sum-ex313_20240331x10qsoni.htm	Edgar Link	pending
sum-ex321_20240331x10q.htm	Edgar Link	pending
smmt-20240331_lab.xml	Edgar Link	unprocessable
smmt-20240331_pre.xml	Edgar Link	unprocessable
smmt-20240331_htm.xml	Edgar Link	completed
smmt-20240331_def.xml	Edgar Link	unprocessable
smmt-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SMMT
Summit Therapeutics Inc. Stock $smmt

2024 Q2 Form 10-Q Financial Statement

#000159929824000085 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMMT Summit Therapeutics Inc. Stock $smmt

2024 Q2 Form 10-Q Financial Statement

#000159929824000085 Filed on May 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMMT
Summit Therapeutics Inc. Stock $smmt